Aripiprazole/sertraline - Otsuka Pharmaceutical

Drug Profile

Aripiprazole/sertraline - Otsuka Pharmaceutical

Alternative Names: ASC-01; Sertraline/aripiprazole

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Amines; Antidepressants; Chlorobenzenes; Mood stabilisers; Naphthalenes; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D2 receptor antagonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Major depressive disorder

Most Recent Events

  • 24 Nov 2017 Chemical structure information added
  • 22 Nov 2017 Otsuka Pharmaceutical plans a phase I bioequivalence trial in healthy volunteers in Japan in November 2017 (JapicCTI-173774)
  • 01 Nov 2017 Otsuka Pharmaceutical initiates enrolment in a phase I bioequivalence trial in healthy volunteers in Japan (JapicCTI173774) (NCT03342963)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top